featured
Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)
J. Clin. Oncol 2020 Apr 28;[EPub Ahead of Print], S Fukuoka, H Hara, N Takahashi, T Kojima, A Kawazoe, M Asayama, T Yoshii, D Kotani, H Tamura, Y Mikamoto, N Hirano, M Wakabayashi, S Nomura, A Sato, T Kuwata, Y Togashi, H Nishikawa, K ShitaraFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.